According to KEYNOTE-059 (25), patients with PD-L1-positive versus PD-L1-negative gastric cancer had a significantly improved objective response rate (15.5% vs. 6.4%) and median duration of response (16.3 vs. 6.9 months). Here, CD274 is linked to gastric cancer.